Naseem et al. studied the frequency and prognosis of double-expressor DLBCL and found that the frequency of c-MYC/BCL-2 co-expression was 14%, with a median survival of 10 months [9]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.